Rakesh Patel

Rivea hypocrateriformis (Desr.) Choisy is a robust woody climbing shrub of the genus Rivea which is widely distributed in India, Nepal, Sri Lanka, Pakistan, Bangladesh, Myanmar, and Thailand. R. hypocrateriformis is a promising medicinal herb with a wide range of beneficial and health-promoting properties. Since the ancient times, it has been used as a traditional medicine to treat rheumatic pain, fever, urogenital problems, snake bites, cough, piles, malaria, and skin diseases. Aside from these traditional uses, its leaves and young shoots are also cooked and eaten as a vegetable and used for the preparation of bread with millet flour. This study extensively analyzes the available information on R. hypocrateriformis botanical characterization, distribution, traditional applications, phytochemistry, pharmacology, and toxicological properties. Phytochemical investigations of the plant has revealed the presence of highly valuable secondary metabolites including alkaloids, glycosides, coumarins, flavonoids, xanthones, stilbenes, and other organic compounds. Its crude extracts and isolated compounds have revealed anovulatory, antifertility, antiarthritic, antimicrobial, anticancer, antioxidant hepatoprotective, antilithiatic, and antimitotic potentials. This review of literature clearly identifies R. hypocrateriformis as a potent medicinal plant with remarkable healing and health-promoting properties. Further research directions into the bioactive extracts, clinical, and toxicological evaluations to assess the beneficial health-promoting properties of this promising herb are also discussed.

BACKGROUND: A prospective multicenter clinical study was performed to evaluate the safety and efficacy of a bovine dermal graft (Xenform® Matrix, Boston Scientific, Natick, MA, USA) during vaginal reconstructive surgery. METHODS: Forty-five women with ICS stage 2 or higher pelvic organ prolapse (POP) were enrolled at 4 centers. POP-Q, pelvic floor function (PFDI-20), sexual function (PISQ-12), and patient satisfaction tools were used to assess subjects at baseline, and at 2 and 6 weeks, and 3, 6 and 12 months post surgery. The significance of symptom score changes at 6 months and 1 year were determined by the t-test for paired data. Forty-three of the 45 patients completed the 12 month study. RESULTS: The majority of the subjects had cystocele (98%) and/or rectocele (84%) defects at study entry. At 12 months, 74% of the defects had improved to a stage 0 or 1. Mean PFDI-20 scores improved by 72% (p < 0.001) at 12 months, and PISQ-12 scores were maintained during the follow-up period indicating no decline in sexual function. Three subjects experienced one serious adverse event each; one of the adverse events (constipation) was deemed by the study physician to be unrelated to Xenform®. One subject had severe pyelonephritis resulting in dialysis. This subject had a previous history of pyelonephritis, sepsis and acute renal failure. The third subject had a reported recurrent cystocele of moderate severity, possibly related to the device. No graft related erosions or pain lasting more than 30 days were reported. No subjects withdrew due to an adverse event. CONCLUSION: This study is the first to investigate the use of Xenform® Matrix in vaginal reconstructive surgery among patients with POP. Significant improvement was maintained at 12 months utilizing both objective and subjective assessment tools, confirming the safety and efficacy of this material in vaginal surgery. TRIAL REGISTRATION: ClinicalTrials.gov NCT01244165.

Abstract Background: Quantitative characterisation of any contagious diseases could help in making effective strategy to prevent further spreading of the disease. Despite the rapid research in prevention of spreading COVID-19, yet there is no quantitatively information about spatiotemporal epidemiology and epidemic intensity of COVID-19. Therefore, we aimed to quantitatively characterize spatiotemporal epidemiology and epidemic intensity of COVID-19 in Indian geography by determine it’s infectability rate, efficacy rate, transmission rate and likelihood of total populations to be infected with COVID-19 in India. Method: Novel statistical model was designed to quantitatively characterize spatiotemporal epidemiology and epidemic intensity of COVID-19. A Retrospective Cohort study was carried out online and offline in Indian geography using a COVID-19 transmission questionnaires sheet that comprises five mandatory questions. The collected offline as well as online data was then entered into a Microsoft excel sheet to obtain primary data and secondary data required for the mathematical model to calculate quantitative data of spatiotemporal epidemiology and epidemic intensity of COVID-19 in India geography. Result and Discussion: Total 539 responses were analysed in the current study out of 557 received responses between April-2021 to May-2021. Average reproductive number of secondary cases was found 0.77. Infectability rate of COIVD-19 patient was found 38.11% while healthy person has 21.08% risk of becoming infected if they expose to the Primary case. J-Index and H-Index were found 55.32% and 4.44%, respectively, indicating that COVID-19 disease outbreaks as severe epidemic disease in India and has potential to infect ~4.44% Indian population. Conclusion: Higher infectability rate (38.11%) of COIVD-19 patient and higher efficacy rate (21.08%) of healthy individual to be infected with COVID-19 outbreak it a severe epidemic in India. COVID-19 potential to infect about 4.44% Indian population, at present, COVID-19 already infected ~2.13% Indian population, which is about 50% of the anticipated population to be infected i.e., 4.44%.